Interferon α for the Therapy of Minimal Residual Disease
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the efficacy of interferon α among patients undergone
unmanipulated blood and marrow transplantation following day 60 post-transplantation who were
minimal residual disease positive after transplantation.
Hematopoietic stem cell transplantation (HSCT) is an effective treatment option for acute
leukemia and many other hematological malignancies. However, post-transplant relapse can
occur in some patients, and the prognosis of these patients is usually very poor.The
persistence or recurrence of minimal residual disease (MRD) in the post-transplant period is
an independent risk factor of relapse. Therefore, MRD monitoring can be used to screen
patients with a high risk of relapse to provide timely intervention and prevent
post-transplant relapse.Interferon α-2b exerts a relatively strong immunomodulatory effect.
It can kill acute leukemia (AL) cells by regulating T-cell and/or natural killer cell
functions.Consequently, interferon α-2b may have potential therapeutic value for AL patients
with MRD-positive after transplantation.
The study hypothesis:
Prevention of relapse using interferon α-2b following hematopoietic stem cell transplantation
in patients with standard risk acute leukemia can reduce relapse rate.